Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04344886
Other study ID # FNO-ENT-Parathyroid_adenoma
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2016
Est. completion date December 31, 2020

Study information

Verified date December 2022
Source University Hospital Ostrava
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The radio-guided technique offers both help with in-vivo identification and ex-vivo confirmation of parathyroid adenoma. In-vivo accuracy is most important but its results are not satisfactory. The aim of this study was to evaluate if there is a beneficial effect of individualized timing of surgery using preoperative multi-phase 99mTc-MIBI single-photon emission computed tomography (SPECT)/CT on in-vivo characteristics of minimally invasive radio-guided parathyroidectomy.


Description:

Despite the relatively accurate preoperative topographic information, minimally invasive parathyroid surgery can still be very challenging, especially in the case of small adenoma in ectopic localization. Radioguided technique offers both help with in-vivo identification and ex-vivo confirmation of adenoma. Excellent ex-vivo radio guidance results are referred. But, in-vivo accuracy is most important but its results are not satisfactory. The aim of this study was to evaluate if there is a beneficial effect of individualized timing of surgery using preoperative multi-phase 99mTc-MIBI single-photon emission computed tomography (SPECT)/CT on in-vivo characteristics of minimally invasive radio-guided parathyroidectomy.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 31, 2020
Est. primary completion date November 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients - No history of thyroid or parathyroid surgery - Diagnosis of primary hyperparathyroidism - Indication for 99mTc-MIBI SPECT/CT examination Exclusion Criteria: - Minor patients - Negative SPECT/CT findings - Patients refusing surgery - Previous combined surgery on the thyroid gland - Patients in high risk of general anesthesia - Patients who do not undergo surgery in the recommended time span

Study Design


Intervention

Procedure:
Conventional (dual-phase) SPECT/CT
Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
Multi-phase SPECT/CT
Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
Conventional minimally-invasive radio-guided parathyroidectomy
Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
Individualised minimally-invasive radio-guided parathyroidectomy
Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.

Locations

Country Name City State
Czechia University Hospital Ostrava Ostrava Moravian-Silesian Region

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Ostrava

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success of surgery (%) Surgery was considered successful if there were lowering of parathyroid hormone serum level and calcemia to normal and histological confirmation of parathyroid gland adenoma/ hyperplasia. 3 months
Primary In-vivo sensitivity (%) Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery. The parathyroid tissue was considered pathologic when the in-vivo radioactive counting was at least 1.15 times more than the background. 3 months
Primary In-vivo specificity (%) Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery. The parathyroid tissue was considered pathologic when the in-vivo radioactive counting was at least 1.15 times more than the background. 3 months
Primary In-vivo accuracy (%) Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery. The parathyroid tissue was considered pathologic when the in-vivo radioactive counting was at least 1.15 times more than the background. 3 months
Primary Ex-vivo sensitivity (%) Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery. Radioactive ex-vivo counts in adenoma/ hyperplastic parathyroid gland greater than 20% of background was used as cutpoint for cure. 3 months
Primary Ex-vivo specificity (%) Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery. Radioactive ex-vivo counts in adenoma/ hyperplastic parathyroid gland greater than 20% of background was used as cutpoint for cure. 3 months
Primary Ex-vivo accuracy (%) Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery. Radioactive ex-vivo counts in adenoma/ hyperplastic parathyroid gland greater than 20% of background was used as cutpoint for cure. 3 months
Secondary Operating time (minutes) The operating time will be measured and recorded. Duration of surgery
Secondary Pathological parathyroid gland volume (ml) The pathological parathyroid gland volume in millilitres will be measured and recorded. Duration of surgery
Secondary Pathological parathyroid gland localisation (ectopic x eutopic) The pathological parathyroid gland localisation (ectopic x eutopic) will be recorded. Duration of surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931109 - Circulating miRNA in Primary Hyperparathyroidism
Completed NCT04305561 - Preoperative Localization Strategies in Primary Hyperparathyroidism N/A
Recruiting NCT03052075 - Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism
Completed NCT03774771 - Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism Phase 2
Recruiting NCT02854345 - Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera N/A
Completed NCT01222026 - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Phase 4
Recruiting NCT00973336 - Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery? Phase 2
Completed NCT01530919 - Minimally Invasive Radioguided Parathyroidectomy N/A
Recruiting NCT03605472 - Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism N/A
Completed NCT01306656 - Vitamin D Repletion in Primary Hyperparathyroidism Phase 4
Terminated NCT00961701 - Lipids Profile in Primary Hyperparathyroidism N/A
Completed NCT00432939 - Primary Hyperparathyroidism: Non-classical Manifestations N/A
Completed NCT00522028 - Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial N/A
Completed NCT03713671 - Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism N/A
Recruiting NCT04969926 - Natural History Study of Parathyroid Disorders
Recruiting NCT03039439 - Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
Not yet recruiting NCT03732157 - Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients
Completed NCT01996072 - EC17 for Intraoperative Imaging for Parathyroidectomy Phase 1
Completed NCT01460030 - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Phase 3
Enrolling by invitation NCT04085419 - Osteoporosis in Primary Hyperparathyroidism Phase 4